Chimeric antigen receptor T-cell (CAR T-cell) and tumor-infiltrating lymphocytes (TILs) therapies in gastrointestinal malignancies: review of literature for clinical applications
Medical Oncology · 2025
DOI: 10.1007/s12032-025-03040-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Oncology, 2025. Verfasst von Mohamed Saad Sayed und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Beni-Suef University, Beni Suef, 62511, Egypt. dr.mohamedsaad11@gmail.com. Hauptthemen laut MEDLINE: Gastrointestinal Neoplasms, Lymphocytes, Tumor-Infiltrating, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beni Suef University.
Abstract (Originalsprache)
Gastrointestinal malignancies (GI malignancies) have had a notoriously dismal prognosis throughout history. The primary therapeutic approaches to treat and manage GI malignancies are immunotherapy, radiotherapy, surgery, and chemotherapy, which may include monotherapy or a combination of these therapies to boost the effect. Nevertheless, the recurrence and metastasis rates remain elevated. In recent decades, immunotherapies have had a powerful impact when included in treatment regimens. In hematologic malignancy, chimeric antigen receptor T cells (CAR-T cell) have shown a promising anticancer impact as one of the immunotherapies. It gives a promising treatment option for solid tumors, including colorectal cancers. In recent clinical trials, the CAR-T cells showed a promising effect on pancreatic, colorectal, esophageal, hepatocellular, and gastric cancers. Tumor-infiltrating lymphocyte (TIL) therapy is another immunotherapy option with promising option for GI malignancies. Through the process of designing the TIL therapy, T cells are extracted and designed according to the nature of the GI malignancy. In this review, we addressed the clinical applications of both therapies while highlighting the challenges and possible strategies to overcome them. CAR T-cells and TIL therapies showed good responses with tolerable and acceptable side effects in treating GI malignancies such as pancreatic, colorectal, gastric, and hepatocellular cancers, while the immunosuppressive tumor microenvironment (TME) inhibiting the activity of immunotherapy and impeding its efficacy is a significant challenge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Beni-Suef University, Beni Suef, 62511, Egypt. dr.mohamedsaad11@gmail.com.
- Faculty of Medicine, Menoufia University, Menoufia, Egypt.
- Medical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA.
- Faculty of Medicine, Alexandria University, Alexandria, Egypt.
- Faculty of Medicine, Cairo University, Cairo, Egypt.
- Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, 31982, Al-Ahsa, Saudi Arabia.
Förderung
- Beni Suef University
Zitieren
APA
Sayed, M. S., Gadelmawla, A. F., Abouelenin, O., Moubarak, E. S., Jibril, N. S., Kandeel, M., & Abdulazeem, H. (2025). Chimeric antigen receptor T-cell (CAR T-cell) and tumor-infiltrating lymphocytes (TILs) therapies in gastrointestinal malignancies: review of literature for clinical applications. Medical Oncology. https://doi.org/10.1007/s12032-025-03040-5
Vancouver
Sayed MS, Gadelmawla AF, Abouelenin O, Moubarak ES, Jibril NS, Kandeel M, et al. Chimeric antigen receptor T-cell (CAR T-cell) and tumor-infiltrating lymphocytes (TILs) therapies in gastrointestinal malignancies: review of literature for clinical applications. Medical Oncology. 2025. doi:10.1007/s12032-025-03040-5
BibTeX
@article{Sayed2025,
author = {Sayed, Mohamed Saad and Gadelmawla, Ahmed Farid and Abouelenin, Osama and Moubarak, Elsayed S and Jibril, Nada S and Kandeel, Mahmoud and Abdulazeem, Hebatullah},
title = {Chimeric antigen receptor T-cell (CAR T-cell) and tumor-infiltrating lymphocytes (TILs) therapies in gastrointestinal malignancies: review of literature for clinical applications},
journal = {Medical Oncology},
year = {2025},
doi = {10.1007/s12032-025-03040-5}
}
EUVIMED